DLD Asset Management’s Crescent Biopharma CBIO Stock Holding History

DLD Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-302	Closed	-$38.2K	–	83
2023 Q1	$38.2K	Buy	+302	New	+$68K	﹤0.01%	106

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DLD Asset Management's CBIO Position: Q2 2023 in Review

DLD Asset Management sold out of Crescent Biopharma (CBIO) in Q2 2023, closing a stake of 292 shares — an estimated $36.8K sold.

DLD Asset Management first reported a position in CBIO in Q1 2023 and held it in 1 quarter. The position peaked at $36.8K in Q1 2023. 55 funds tracked by Wall St. Rank hold CBIO as of Q2 2023.

DLD Asset Management reported no remaining Crescent Biopharma position as of Q2 2023 after selling out during the quarter.
DLD Asset Management sold 292 Crescent Biopharma shares in Q2 2023, an estimated $36.8K.
DLD Asset Management first reported a position in Crescent Biopharma in Q1 2023 and held it in 1 quarter.
DLD Asset Management's Crescent Biopharma position peaked at $36.8K in Q1 2023.
55 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2023.

Based on DLD Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.